Brooks Elizabeth, Burns Megan, Ma Ran, Scholten Henk Jan, Becker Shawn
TTi Health Research and Economics, Westminster, MD, USA.
Siren Care, Inc, San Francisco, CA, USA.
Clinicoecon Outcomes Res. 2021 Oct 7;13:873-881. doi: 10.2147/CEOR.S322424. eCollection 2021.
Foot temperature monitoring for the prevention and early detection of diabetic foot ulcers (DFU) is evidence-based and recommended in clinical practice. However, easy-to-use remote monitoring tools have been lacking, thereby preventing widespread adoption.
To evaluate the cost-effectiveness of remote foot temperature monitoring (RFTM) (Siren's Neurofabric™ Diabetic socks) in addition to standard of care (SoC) versus SoC alone for early detection of DFU with diabetic neuropathy and a moderate to high risk of DFU.
A payer perspective decision-tree analysis was conducted to compare expected DFU occurrence and subsequent amputation rates and costs between treatment strategies over one year. Inputs in the model were sourced from publicly available literature and relevant health technology assessments. One-way sensitivity analyses were performed for each model variable.
In the base-case scenario, RFTM plus SoC was a dominant strategy compared to SoC alone. RFTM plus SoC was associated with cost savings of $38,593 per additional ulcer avoided versus SoC alone, and $8027 per patient per year on average compared to SoC alone. These results were highly robust to one-way sensitivity analysis; all scenarios remained dominant if compliance was ≥13%.
RFTM is a cost-effective addition to SoC in patients with diabetic neuropathy at a moderate-to-high risk of DFU and subsequent amputation. Further, reduction in DFU and associated complications may result in improvements in the patient's quality of life and mental health. Future studies are needed to evaluate the compliance and reduction of DFU occurrence in patients on RFTM.
足部温度监测用于预防和早期发现糖尿病足溃疡(DFU)是有循证依据的,且在临床实践中得到推荐。然而,一直缺乏易于使用的远程监测工具,从而阻碍了其广泛应用。
评估除标准治疗(SoC)外,远程足部温度监测(RFTM)(Siren's Neurofabric™糖尿病袜)联合SoC与单纯SoC相比,在早期发现伴有糖尿病神经病变且DFU风险为中度至高度的DFU方面的成本效益。
从支付方角度进行决策树分析,以比较两种治疗策略在一年时间内DFU的预期发生率、后续截肢率及成本。模型中的数据来源于公开文献和相关卫生技术评估。对每个模型变量进行单向敏感性分析。
在基础病例情景中,与单纯SoC相比,RFTM联合SoC是一种优势策略。与单纯SoC相比,RFTM联合SoC每多避免一例溃疡,可节省成本38,593美元,平均每位患者每年比单纯SoC节省8027美元。这些结果对单向敏感性分析具有高度稳健性;如果依从性≥13%,所有情景仍具有优势。
对于有中度至高度DFU及后续截肢风险的糖尿病神经病变患者,RFTM是SoC的一种具有成本效益的补充。此外,DFU及其相关并发症的减少可能会改善患者的生活质量和心理健康。未来需要开展研究,以评估使用RFTM患者的依从性以及DFU发生率的降低情况。